Log in

The Medicines Price Target, Predictions & Analyst Ratings

Notice: This company has been marked as potentially delisted and may not be actively trading.
0.00 (0.00 %)
(As of 01/6/2020)
Today's Range
Now: $84.90
50-Day Range
MA: $84.90
52-Week Range
Now: $84.90
Average Volume9.55 million shs
Market Capitalization$6.77 billion
P/E RatioN/A
Dividend YieldN/A

Analyst Ratings

The Medicines (NASDAQ:MDCO) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
6 Wall Street analysts have issued ratings and price targets for The Medicines in the last 12 months. Their average twelve-month price target is $76.50, predicting that the stock has a possible downside of 9.89%. The high price target for MDCO is $85.00 and the low price target for MDCO is $59.00. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
MDCO Consensus Rating: HoldHoldBuyBuy
MDCO Consensus Rating Score:
MDCO Analyst Ratings: 0 Sell Rating(s)
5 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
MDCO Consensus Price Target: $76.50$75.50$76.75$76.75
MDCO Price Target Upside: 9.89% downside12.85% upside30.62% upside30.62% upside

The Medicines (NASDAQ:MDCO) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

The Medicines (NASDAQ:MDCO) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/26/2019SVB LeerinkDowngradeOutperform ➝ Market Perform$78.00 ➝ $85.00Low
11/26/2019Chardan CapitalDowngradeBuy ➝ NeutralLow
11/25/2019OppenheimerDowngradeOutperform ➝ Hold$68.00 ➝ $85.00High
11/25/2019Robert W. BairdDowngradeOutperform ➝ Neutral$100.00 ➝ $85.00Medium
11/25/2019CowenReiterated RatingBuy$60.00Low
11/20/2019CitigroupReiterated RatingHold$59.00High
10/10/2019Jefferies Financial GroupDowngradeBuy ➝ Hold$44.00 ➝ $50.00High
10/2/2019B. RileyBoost Price TargetBuy$74.00 ➝ $95.00Low
9/3/2019Roth CapitalSet Price TargetBuy$72.00Low
9/3/2019JPMorgan Chase & Co.Boost Price TargetOverweight$39.00 ➝ $49.00Medium
9/2/2019Piper Jaffray CompaniesReiterated RatingOverweight ➝ Positive$142.00 ➝ $145.00High
8/26/2019Bank of AmericaReiterated RatingBuy$51.00High
4/26/2019The Goldman Sachs GroupUpgradeNeutral ➝ Buy$25.00 ➝ $55.00High
12/14/2018Wolfe ResearchInitiated CoverageOutperform ➝ OutperformLow
(Data available from 10/30/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 10/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.